Eli Lilly and Co (LLY) reported last week that its anti-diabetic drug Peglispro showed better results in its Phase-III trials compared to the already approved Sanofi (SNY) Lantus.
This once-daily insulin treatment is capable of reducing blood sugar levels in type 1 and 2 diabetic patients. Lilly plans to file the New Drug Approval (NDA) for Peglispro by early 2015 in US and Europe.
Eli Lilly and Co (LLY) announced on Monday, that the US Food and Drug Administration (FDA) had given tentative approval to its diabetes insulin drug called Basaglar. The development of this drug, which is administered intraveneously and aims to control blood sugar levels in diabetic patients, is a joint effort by Eli Lilly and Boehringer Ingelheim Corporation.
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes. The battle started with the launch of Sanofi’s Lantus (insulin glargine) and Novo’s Levemir. Both drugs fall under the category of long-acting basal insulin used for controlling the blood glucose levels in diabetic patients.
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Data from the trials was presented at the European Association for the Study of Diabetes (EASD) held in Vienna from September 16-19.
David Damiano would have died before his first birthday if it weren't for modern medicine. David received a diagnosis of type 1 diabetes at 11 months old. His pancreas stopped producing insulin, the hormone that regulates how much sugar is in our blood. Too much and you can end up in a coma, too little and your organs stop working.
On Friday, the US Food & Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Co.’s (LLY) drug Jardiance (empagliflozin) as an add-on to diet and exercise to improve glycemic control (blood sugar levels) in adults with type 2 diabetes (T2D). The approval comes after the FDA had earlier rejected empagliflozin because of manufacturing deficiencies at Boehringer’s facility, where the drug is manufactured.
Sanofi SA ADR (SNY) announced today that the French-based pharmaceutical giant has entered into a licensing agreement with Mannkind Corporation (MNKD) for the manufacture and marketing of the insulin inhaler Afrezza.
The announcement comes after the Food and Drug Administration (FDA) approved Afrezza for marketing on June 27. Sanofi and Mannkind plan to launch the drug in the US in early 2015.